These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38274492)

  • 21. A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients.
    Erken R; Loukachov VV; de Niet A; Jansen L; Stelma F; Helder JT; Peters MW; Zaaijer HL; Kootstra NA; Willemse SB; Reesink HW
    J Clin Exp Hepatol; 2022; 12(3):735-744. PubMed ID: 35677522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
    Janssen HLA; Hou J; Asselah T; Chan HLY; Zoulim F; Tanaka Y; Janczewska E; Nahass RG; Bourgeois S; Buti M; Lampertico P; Lenz O; Verbinnen T; Vandenbossche J; Talloen W; Kalmeijer R; Beumont M; Biermer M; Shukla U
    Gut; 2023 Jul; 72(7):1385-1398. PubMed ID: 36697207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
    Yuen MF; Heo J; Jang JW; Yoon JH; Kweon YO; Park SJ; Tami Y; You S; Yates P; Tao Y; Cremer J; Campbell F; Elston R; Theodore D; Paff M; Bennett CF; Kwoh TJ
    Nat Med; 2021 Oct; 27(10):1725-1734. PubMed ID: 34642494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.
    Gane EJ; Kim W; Lim TH; Tangkijvanich P; Yoon JH; Sievert W; Sukeepaisarnjaroen W; Thompson AJ; Pavlovic V; Surujbally B; Wat C; Brown BD; Achneck HE; Yuen MF
    J Hepatol; 2023 Nov; 79(5):1139-1149. PubMed ID: 37524230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy.
    Piratvisuth T; Komolmit P; Chan HL; Tanwandee T; Sukeepaisarnjaroen W; Pessoa MG; Fassio E; Ono SK; Bessone F; Daruich J; Zeuzem S; Manns M; Uddin A; Dong Y; Trylesinski A
    Drugs Context; 2016; 5():212294. PubMed ID: 27403192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
    Reyes M; Lutz JD; Lau AH; Gaggar A; Grant EP; Joshi A; Mackman RL; Ling J; Tan SK; Ayithan N; Daffis S; Woo J; Wu P; Lam T; Fletcher SP; Kottilil S; Poonia B; Gane EJ; Mathias A; German P
    Antivir Ther; 2020; 25(3):171-180. PubMed ID: 32667286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
    Pan CQ; Chan S; Trinh H; Yao A; Bae H; Lou L
    World J Gastroenterol; 2015 May; 21(18):5524-31. PubMed ID: 25987775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg- positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA].
    Wang FD; Zhou J; Zhang DM; Wang ML; Tao YC; Wu DB; Tang H; Chen EQ
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):389-394. PubMed ID: 35545563
    [No Abstract]   [Full Text] [Related]  

  • 32. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C.
    Xu JH; Wang S; Zhang DZ; Yu YY; Si CW; Zeng Z; Xu ZN; Li J; Mao Q; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
    World J Clin Cases; 2022 Oct; 10(28):10085-10096. PubMed ID: 36246814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
    Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
    J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
    Huang M; Li X; Wu Y; Tao L; Jie Y; Li X; Shi H; Lin G; Yang F; Ao Y; Pang Y; Zhang M; Chong Y
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):266-71. PubMed ID: 25173224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA.
    Gao WK; Shu YY; Chen Y; Ai Y; Yang XQ; Du F; Ye J
    J Clin Transl Hepatol; 2022 Feb; 10(1):112-119. PubMed ID: 35233379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
    Sulkowski MS; Agarwal K; Ma X; Nguyen TT; Schiff ER; Hann HL; Dieterich DT; Nahass RG; Park JS; Chan S; Han SB; Gane EJ; Bennett M; Alves K; Evanchik M; Yan R; Huang Q; Lopatin U; Colonno R; Ma J; Knox SJ; Stamm LM; Bonacini M; Jacobson IM; Ayoub WS; Weilert F; Ravendhran N; Ramji A; Kwo PY; Elkhashab M; Hassanein T; Bae HS; Lalezari JP; Fung SK; Yuen MF
    J Hepatol; 2022 Nov; 77(5):1265-1275. PubMed ID: 35697332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
    Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A
    Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.